List view / Grid view
New trial data shows Novavax’s COVID-19 vaccine, NVX–CoV2373, is effective…
New trial data shows Novavax’s COVID-19 vaccine, NVX–CoV2373, is effective against both the B.1.1.7 UK and the B1.351 South African variants.
Novavax’s NVX-CoV2373 vaccine candidate was 89.3 percent effective overall and…
Novavax’s NVX-CoV2373 vaccine candidate was 89.3 percent effective overall and 85.6 percent effective against the B.1.1.7 SARS-CoV-2 variant, in a Phase III trial.
The Canadian government has agreed that Janssen will supply the…
The Canadian government has agreed that Janssen will supply the country with 38 million doses of its COVID-19 vaccine, while Novavax has agreed to supply 76 million doses if its vaccine.
Novavax and FUJIFILM Diosynth Biotechnologies have agreed for FDB to…
Novavax and FUJIFILM Diosynth Biotechnologies have agreed for FDB to make the bulk drug substance for NVX-CoV2373, the Novavax COVID-19 vaccine candidate.
